ESMO 2022: Preop Neoadjuvant Nivolumab + Ipilimumab Tied to No Disease Recurrence
Among patients with mismatch repair status-deficient colon cancer, 95 percent had major pathogenic response and few adverse events
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.